ClinicalTrials.gg
Not yet recruitingNCT06574048CODexUpdated Aug 14, 2026

Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

A Phase 1/2 interventional study of saline placebo and Dexamethasone in Carbon Monoxide Poisoning, Carbon Monoxide Intoxication and Carbon Monoxide Encephalopathy, sponsored by University of Nebraska. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by University of Nebraska · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Carbon Monoxide Poisoning with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Carbon Monoxide Poisoning · United States.

Started
2026
the only one that year
Phase 1/2
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
University of Nebraska

Among the 12 studies in Carbon Monoxide Poisoning with a site in United States, this one is the only one that started in 2026, is the only one in phase 1/2, and was the 12th registered.

Carbon Monoxide Poisoning

44 studies on the registry are indexed under Carbon Monoxide Poisoning; 8 are open to participants now.

Browse Carbon Monoxide Poisoning studies →

Open to participants now

2 of the 12 studies in Carbon Monoxide Poisoning with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Carbon Monoxide Poisoning studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carbon Monoxide Poisoning with a site in United States, or all of them as a file.
02

Study summary

Hyperbaric Oxygen Therapy (HBO) is routine treatment of carbon monoxide (CO) poisoning to prevent delayed neurological sequelae. This study looking to see if neurologic outcomes are improved with the addition of dexamethasone. CO poisoning can initiate a free radical mediated process that can instigate a demyelinating process resulting in long term neurological sequelae in some, but not all patients. In other demyelinating disorders, steroids are a part of first line treatment. HBO is already used for acute CO poisoning, so this pilot study will try to ascertain if the addition of steroids in concert with each hyperbaric oxygen session will yield improved outcomes.

Read the detailed description

Hyperbaric Oxygen Therapy (HBO) is routine treatment of carbon monoxide (CO) poisoning to prevent delayed neurological sequelae. This study looking to see if neurologic outcomes are improved with the addition of dexamethasone. CO poisoning can initiate a free radical mediated process that can instigate a demyelinating process resulting in long term neurological sequelae in some, but not all patients. In other demyelinating disorders, steroids are a part of first line treatment. HBO is already used for acute CO poisoning, so this pilot study will try to ascertain if the addition of steroids in concert with each hyperbaric oxygen session will yield improved outcomes.

The control group will receive three HBO treatment sessions plus placebo. The treatment group will receive three HBO treatment sessions plus 10 mg Dexamethasone per day during HBO therapy (minimum of two doses, up to a maximum of five doses if participant stays for longer than three days). After three treatment sessions, the participant will be discharged home barring no other medical complications requiring further hospitalization. In two weeks, participants will return for follow-up testing and evaluation. Continued HBO therapy plus placebo as well as HBO therapy plus steroids for respective group members will be offered if participants are still dealing with CO poisoning sequelae as determined by our outcome measures. In addition, a 6 week and 12 week telephone follow-up will be conducted asking questions regarding memory, emotion, neurologic symptoms.

03

Conditions studied

  • Carbon Monoxide Poisoning
  • Carbon Monoxide Intoxication
  • Carbon Monoxide Encephalopathy
  • Carbon Monoxide-induced Parkinsonism
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute CO poisoning, intentional or non-intentional exposure, receiving HBO treatment during hospitalization
  • Age >18 years
  • Nebraska Medicine admission

Exclusion criteria

Exclusion Criteria:

  • Mechanical ventilation
  • No hospital admission or admission to hospital Critical Care Medicine Service
  • Allergy to dexamethasone
  • Pre-Existing neurological condition confounding outcome determination
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Hyperbaric Oxygen Therapy with Dexamethasone

    Participants will be treated with hyperbaric oxygen (HBO) therapy within three days of acute carbon monoxide poisoning. Treatment is a minimum of three inpatient sessions. Participants will also receive 10 mg dexamethasone per day while receiving HBO therapy (minimum of two doses, maximum of five doses if participants' stay is longer than three days). After three treatment sessions, participants will discharge home, barring no other medical complications requiring further hospitalization. In addition, continued HBO therapy plus steroids will be offered if participants are still dealing with CO poisoning sequelae as determined by study outcome measures.

    Drug: Dexamethasone

  • Placebo comparator
    Hyperbaric Oxygen Therapy with Placebo (Saline)

    Participants will be treated with hyperbaric oxygen (HBO) therapy within three days of acute carbon monoxide poisoning. Treatment is a minimum of three inpatient sessions. Participants will also a saline placebo instead of dexamethasone while receiving HBO therapy. After three treatment sessions, participants will discharge home, barring no other medical complications requiring further hospitalization. In addition, continued HBO therapy plus steroids will be offered if participants are still dealing with CO poisoning sequelae as determined by study outcome measures.

    Drug: saline placebo

Interventions

  • Drugsaline placebo

    IV saline bolus

    Also known as: nebulized normal saline (NS) placebo

  • 10mg IV Dexamethasone

    Also known as: Ozurdex, Maxidex, DexPak 10 day, DexPak 6 Day, LoCort, DoubleDex, ReadySharp dexamethasone, DexPak 13 Day, ZonaCort

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction that assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuo-constructional skills, conceptual thinking, calculations, and orientation. The MoCA will be given in person while inpatient and via phone after discharge. Scored 0-30 Normal Cognitive performance 26 and above Mild impairment 18-25 Moderate impairment 10-17 Severe impairment 0-9

    Time frame: Prior to hospital discharge after HBO therapy is no longer clinically warranted, and post-discharge at 2 weeks, 6 weeks, and 12 weeks.

Secondary outcomes

  1. Memory, Emotion, and Neurologic Symptoms

    Post-treatment phone followup

    Time frame: 6 weeks and 12 weeks post-treatment

07

Study locations

1 site
  • Nebraska Medicine, Hyperbaric Medicine Program, Clarkson Tower
    Omaha, Nebraska 68105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 27, 2024
StartEst.
Oct 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2028
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06574048
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Oct 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 14, 2026

Study contacts

Jeffrey S Cooper, MD
Contact
jeffrey.cooper@unmc.edu
402-552-2490
Brooklin Zimmerman, MSN
Contact
brooklin.zimmerman@unmc.edu
402-559-5237
Jeffrey S Cooper, MD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion